BCVA, anatomic improvements found with OPT-302 combination therapy for PCV
At ARVO 2022, Dr Jason S. Slakter presents data on the efficacy and safety of OPT-302 when combined with ranibizumab for polypoidal choroidal vasculopathy.
Emily Kaiser, editor of Modern Retina™, sits down with Dr Jason S. Slakter to discuss his ARVO 2022 presentation, “Efficacy and Safety of OPT-302 in Combination with Ranibizumab for Polypoidal Choroidal Vasculopathy.” OPT-302 (Opthea Limited) 2 mg combination therapy results indicated a safety profile consistent with the standard of care anti-VEGF-A monotherapy, but also indicated superior improvements in best-corrected visual acuity (BCVA) and anatomic improvements compared to monthly ranibizumab (Lucentis®) monotherapy in patients with polypoidal choroidal vasculopathy (PCV).
AAO 2023: Marco A. Zarbin, MD, PhD, provides analysis of the YOSEMITE and RHINE clinical trials
November 24th 2023At this year's American Academy of Ophthalmology meeting in San Francisco, California, Marco A. Zarbin, MD, spoke with Ophthalmology Times about his team's post-hoc analysis of the YOSEMITE and RHINE clinical trials
